Long-term outcome of patients treated for craniopharyngioma: a single center experience. 2023

Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.

Treatment of craniopharyngiomas (CP) is challenging due to their proximity to critical neural structures, risk of serious complications and impaired quality of life after treatment. Recurrences may occur many years after surgical resection. However, long-term outcome data are still scarce. The purpose of this retrospective study was therefore to assess the long-term results after treatment of patients with CP. Patients surgically treated for a histologically verified CP at Oslo University Hospital between 1992 and 2015 and with at least a 5-year follow-up were included. Patients' medical records and radiological studies were reviewed. Sixty-one patients (mean age 35.8 ± 22.2 years) were included; 18 patients (30%) were children <18 years of age. The incidence for the study period and the referral population was 1.1 cases/million/year, with trimodal peak incidence at 6, 32 and 59 years of age. The commonest presenting symptoms were visual disturbances (62%), headache (43%) and endocrine dysfunction (34%). The transcranial approach was utilized in 79% of patients. Gross total resection (GTR) was achieved in 59%. The surgical complication rate was 20%. Three patients (5%) received radiotherapy or radiosurgery after primary resection. The mean follow-up was 139 ± 76 months, with no patients lost to follow-up. Postoperatively, 59% of patients had panhypopituitarism and 56% diabetes insipidus. Eighteen patients (30%) developed tumour recurrence after a mean follow-up of 26 ± 25 months. The 10-year overall survival (OS) rate was 75%, whereas the disease-specific survival (DSS) rate was 84%, and recurrence-free survival (RFS) 61%. Subtotal resection (STR) (p = .01) and systemic comorbidity (p = .002) were associated with worse DSS. Surgical treatment of CP, even though combined with adjuvant radiotherapy in only selected cases, provides good long-time OS and DSS, and relatively good functional outcome in long-term survivors despite postoperative morbidity, particularly endocrine dysfunction. Systemic comorbidity and STR are individual negative prognostic factors.

UI MeSH Term Description Entries

Related Publications

Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
August 2017, Journal of clinical immunology,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
April 2010, Bosnian journal of basic medical sciences,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
January 2011, Clinical transplantation,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
July 2013, Middle East journal of digestive diseases,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
August 2019, Telemedicine journal and e-health : the official journal of the American Telemedicine Association,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
December 2016, Pituitary,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
January 2021, PloS one,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
February 2018, World journal of surgery,
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
December 2010, Pediatric nephrology (Berlin, Germany),
Radek Frič, and Marton König, and Bernt J Due-Tønnessen, and Jon Ramm-Pettersen, and Jon Berg-Johnsen
January 2022, Neurocirugia (English Edition),
Copied contents to your clipboard!